Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study.
Caterina LapucciJessica FrauEleonora CoccoGiancarlo CogheMaria PetraccaRoberta LanzilloVincenzo Brescia MorraCarolina Gabri NicolettiDoriana LandiGirolama MarfiaMarco VercellinoPaola CavallaAssunta BiancoMassimiliano MirabellaValentina Torri ClericiEugenia TomasMaria Teresa FerròPaola GrossiAgostino NozzolilloMoiola LMauro ZaffaroniMarco RonzoniFederica PinardiGiovanni NoviMaria CellerinoAntonio UccelliMatilde InglesePublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2024)
OCR after two ALM courses seemed to be safe and effective. Early IgM hypogammaglobulinemia occurred in a high proportion of patients. The evidence of inflammatory activity between ALM courses seemed to increase the risk of MS re-activation on OCR treatment.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- mass spectrometry
- multiple sclerosis
- end stage renal disease
- ejection fraction
- ms ms
- rheumatoid arthritis patients
- ankylosing spondylitis
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- juvenile idiopathic arthritis
- patient reported outcomes
- combination therapy